Lexicon Pharmaceuticals | LXRX - Current Assets


Lexicon Pharmaceuticals reported $101.9M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Illumina USD 2.74B 551M Mar/2026
Insmed USD 1.79B 137.6M Dec/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
J&J USD 59.17B 3.55B Mar/2026
Lexicon Pharmaceuticals USD 101.9M 20.63M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
MannKind USD 291.58M 67.26M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025